Cirtec Medical Corp.

Cirtec Medical Corp. , based in the US, specializes in the engineering and manufacturing of advanced medical devices, concentrating on minimally invasive solutions and active implantable devices. Founded in 1987 and headquartered in Brooklyn Park, US, Cirtec Medical Corp. focuses on the design and production of medical devices.

The company underwent a Secondary Buyout in July 2017, raising USD 136. 00 mn with investor 3i, marking a significant development in its funding history. Elizaeth Abraham currently serves as the CEO. Cirtec Medical specializes in the engineering and manufacturing of advanced medical devices, focusing on minimally invasive solutions, active implantable devices, and precision components.

Their core offerings include precision-engineered catheter systems, silicone and polyisoprene materials for implantable devices, and a range of medical tubing designed for optimal biocompatibility and reliability. These products address critical healthcare needs in cardiology, neurology, and drug delivery systems. Cirtec serves a diverse clientele, including leading medical device companies across North America, Europe, and Asia, ensuring that their innovations meet the complex demands of various markets. Their commitment to quality and compliance has positioned them as a trusted partner for clients developing complex Class II and III medical technologies.

Cirtec Medical's revenue is derived from B2B transactions with a focus on strategic partnerships and collaborations with prominent medical device manufacturers. Transactions typically involve customized contract agreements where clients engage Cirtec for specific design, development, and manufacturing services tailored to their unique needs. The company provides a range of products, including advanced catheter technologies and precision metals, which are priced according to the complexity and specifications of each project. Through their robust corporate quality management system, Cirtec ensures that they meet the stringent requirements of their clients, further solidifying partnerships that drive revenue growth.

Their business model emphasizes direct engagement with healthcare technology developers, facilitating streamlined processes that enhance market readiness for their innovative solutions. Cirtec Medical plans to leverage its recent funding of USD 136. 00 mn from the Secondary Buyout to support the development and launch of new products, particularly in minimally invasive medical technologies. The company is targeting expansion into new geographic regions, specifically focusing on the Asian market by 2025.

In July 2017, the influx of capital was aimed at enhancing their product development capabilities and scaling their manufacturing operations to meet growing demand.